Primary prostate cancer is the most common malignancy in men but has highly variable
outcomes, highlighting the need for biomarkers to determine which patients can be …

The level of copy number alteration (CNA), termed CNA burden, in the tumor genome is
associated with recurrence of primary prostate cancer. Whether CNA burden is associated …

Background Understanding the heterogeneous genotypes and phenotypes of prostate
cancer is fundamental to improving the way we treat this disease. As yet, there are no …

Background Global disparities in prostate cancer (PCa) incidence highlight the urgent need
to identify genomic abnormalities in prostate tumors in different ethnic populations including …

Prostate cancer is the most commonly diagnosed non-cutaneous neoplasm among
American males and is the second leading cause of cancer-related death. Prostate specific …

Purpose A long natural history and a predominant osseous pattern of metastatic spread are
impediments to the adoption of precision medicine in patients with prostate cancer. To …

BACKGROUND This study sought to identify novel effectors and markers of localized but
potentially life‐threatening prostate cancer (PCa), by evaluating chromosomal copy number …

Background Patients with prostate cancer may present with metastatic or recurrent disease
despite initial curative treatment. The propensity of metastatic prostate cancer to spread to …

DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate
cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic …

Aneuploidy, defined as chromosome gains and losses, is a hallmark of cancer. However,
compared with other tumor types, extensive aneuploidy is relatively rare in prostate cancer …